BridgeMD
New treatment option for Guillain-Barre Syndrome
Official title Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome
ClinicalTrials.gov ID: NCT06996509
What this study is testing
- What it's testing
- This study will involve 70 adult patients with Guillain-Barré syndrome who have severe breathing problems. It will compare two types of breathing support: high-velocity nasal cannula (HVNC) (which delivers heated and humidified air at 35-60 L/min) and bi-level noninvasive ventilation (NIV) (which uses two pressure levels: inspiratory positive airway pressure (IPAP) 10-16 cmH₂O and expiratory positive airway pressure (EPAP) 5-8O).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- GBS per Brighton criteria (clinical ± cerebrospinal fluid (CSF)/electrodiagnostics)
- Moderate acute respiratory failure (vital capacity (VC) 15-20 mL/kg and/or arterial partial pressure of carbon dioxide (PaCO₂) \> 45 mmHg or arterial...
- Hughes Grade 3-4, The Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score (EGRIS) 1-3, Medical Research Council (MRC) sum score 20-40
- Glasgow Coma Scale (GCS) ≥ 13, intact cough/gag, stable hemodynamics
You likely can't join if
- Chronic respiratory disease (COPD, interstitial lung diseases (ILD), persistent asthma)
- Immediate need for invasive ventilation (VC \< 10 mL/kg, unresponsive severe gas-exchange derangement)
- Severe bulbar dysfunction or prior intubation for the current illness
- Contraindications to HVNC/NIV (facial trauma, untreated pneumothorax, agitation, vomiting)
- Pregnancy
- Severe comorbidity limiting prognosis.
See the full eligibility criteria
- Age ≥ 18 years
- GBS per Brighton criteria (clinical ± cerebrospinal fluid (CSF)/electrodiagnostics)
- Moderate acute respiratory failure (vital capacity (VC) 15-20 mL/kg and/or arterial partial pressure of carbon dioxide (PaCO₂) \> 45 mmHg or arterial partial pressure of oxygen (PaO₂) \ 24 /min)
- Hughes Grade 3-4, The Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score (EGRIS) 1-3, Medical Research Council (MRC) sum score 20-40
- Glasgow Coma Scale (GCS) ≥ 13, intact cough/gag, stable hemodynamics
- Onset of respiratory symptoms ≤ 7 days
- Chronic respiratory disease (COPD, interstitial lung diseases (ILD), persistent asthma)
- Immediate need for invasive ventilation (VC \< 10 mL/kg, unresponsive severe gas-exchange derangement)
- Severe bulbar dysfunction or prior intubation for the current illness
- Contraindications to HVNC/NIV (facial trauma, untreated pneumothorax, agitation, vomiting)
- Pregnancy
- Severe comorbidity limiting prognosis.
- Declined consent
The study team makes the final eligibility decision.
Where it's taking place
- Asyut, Assuit, Egypt
- Asyut, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Asyut, Assuit, Egypt; Asyut, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.